Femaford 2.5 mg Tablet (Letrozole)

About this Medicine

Femaford 2.5 mg Tablet, containing the active ingredient Letrozole, is a vital prescription medication categorized as an aromatase inhibitor. Specifically designed for postmenopausal women, it plays a crucial role in the treatment of hormone-receptor-positive (HR+) breast cancer. After menopause, the ovaries stop producing estrogen, but the body still produces small amounts in other tissues, primarily fat, through an enzyme called aromatase. Femaford works by blocking this enzyme, thereby significantly reducing the production of estrogen throughout the body. The primary goal of Femaford 2.5 mg is to lower estrogen levels, as estrogen can fuel the growth of HR+ breast cancer cells. By inhibiting estrogen production, Femaford helps to slow or stop the growth of these cancer cells. This medication is typically prescribed as an adjuvant treatment following surgery, to help prevent the recurrence of breast cancer, or as a first-line treatment for advanced breast cancer. It may also be used in women whose cancer has spread to other parts of the body or those who have had previous anti-estrogen therapy. As a potent therapeutic agent, Femaford 2.5 mg requires a prescription and should only be used under the careful guidance and supervision of a qualified healthcare professional who can assess its suitability for your specific medical condition and monitor for potential side effects. Always discuss your complete medical history and any current medications with your doctor before starting treatment with Femaford.